Skip to main content

Table 3 Reporting rates per 100,000 drug prescriptions/drug prescriptions for different patients

From: Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs

The five drug substances reported most frequently between 01/01/2000–28/2/2019* (number of ADR reports between 01/01/2009–28/02/2019) a Reporting rate per 100,000 drug prescriptions b Reporting rate per 100,000 drug prescriptions for different patients b
Etanercept (n = 302) 546.6 4946.8
Palivizumab (n = 325) c 86.3 446.1
Atomoxetine (n = 178) 19.8 229.5
Methylphenidate (n = 604) 5.8 85.4
Ibuprofen (n = 339) 0.6 2.2
  1. apresented are the five drug substances most frequently reported. Single drug substances and their combination products (if available) were summarized
  2. bcalculation of reporting rates: number of ADR reports/number of drug prescriptions or number of ADR reports/number of drug prescriptions for different patients)
  3. cADR reports for palivizumab were mostly related to a lack of efficacy
  4. Table 3 presents the ranking of the reporting rates for the five drug substances most frequently reported in the complete data set (see Table 1). The reporting rate was calculated for the time period 01/01/2009–28/02/2019, since substance-specific exposure data were only available for this time